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Background who have objective evidence of MI.6 The ECG is dif-
ficult to interpret in the post-operative setting and often
Peri-operative myocardial infarction (MI) occurs in does not display the classical ST segment elevation of
acute myocardial infarction.7 Lastly, even if there is a5–10% of patients undergoing major vascular surgery,
is fatal in 50% of these cases and in total will account significant rise in creatine kinase leaked from dying
myocardial cells (CK-MB) this may be masked byfor more than 50% of all post-operative deaths.1 An
even larger proportion of operated patients will suffer large quantities of creatine kinase (CK) released from
skeletal muscle as the result of direct surgical traumacardiac complications, which may be fatal or non-fatal,
that are not demonstrably related to peri-operative or ischaemia/reperfusion injury.8 This makes the CK/
CK-MB ratio difficult to interpret.MI.2 These complications may have metabolic causes,
but are perhaps more likely to be due to myocardial
infarction that cannot be detected by the standard
diagnostic tests for peri-operative MI.3,4 This injury
Micro-infarction and the acute coronarymay be referred to as minor myocardial injury or
syndromesmicro-infarction.
Defining the aetiology, incidence, and treatment of
Recently it has become possible to detect micro-in-peri-operative cardiac complications has been
farction by measuring cardiac structural proteins, suchhampered by the limitations inherent in World Health
as cardiac troponin, that are released following myo-Organisation (WHO) criteria for diagnosis of acute MI.
cardial cell death.9–11 It has become apparent that evenThe WHO criteria require that two of the following
though the occurrence of micro-infarction may not leadthree features are present: a history of characteristic
to an acute deterioration of left ventricular function, itprolonged ischaemic chest pain; evolutionary changes
is associated with a very adverse longer term prog-on the electrocardiogram (ECG) and elevation of serial
nosis.9 Most studies conducted with regard to thiscardiac enzymes.5 However, in post-operative patients,
have focused on the acute coronary syndromes. This issymptoms may be masked by the use of opiate anal-
a group of conditions characterised by the spontaneousgesia, and atypical or even absent in up 75% of patients
development of myocardial ischaemia due to the ero-
sion, fissuring or rupture of coronary atherosclerotic
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electrocardiogram, and the later development of Q Troponin as a specific marker of myocardial
injurywaves as a result of myocardial scarring. At the other
extreme, no infarction occurs, and the electro-
Troponin I and T, but not C, exist as distinct cardiaccardiogram usually shows non-specific changes such
as ST depression or T wave inversion, and returns to specific sub-types.25 These structural, and therefore,
antigenic differences have allowed the developmentnormal once the symptoms settle. Between these two
extremes lie a large group of patients who will have of specific monoclonal antibodies to cardiac troponin
I (cTnI) and T (cTnT). Both qualitative and quantitativesuffered micro-infarction.
While it was originally felt that their prognosis was assays based on these antibodies have been approved
by the United States Food and Drug Administrationmore favourable in the absence of acute MI, it is now
apparent that by 30 days they have a disturbingly (FDA) for use in clinical diagnosis.26 cTnI and T are
released from myocardial cells early following cellhigh mortality that may actually exceed that of patients
who present with full thickness MI.13,14 There appears necrosis and remain elevated in the circulation for a
considerable time (Table 1).to be a gradation of risk, with poorer outcome being
associated with a larger micro-infarction.9 Recognition
of the occurrence of micro-infarction and its seemingly
poorer prognosis has led to a recent re-definition
Clinical experience with cTnTof term myocardial infarction so that some patients
previously classified as suffering from unstable angina,
To date, most experience has been gained with cTnT.are now re-classified as having had small myocardial
There is one standardised assay for both qualitativeinfarcts.15 Though the mechanisms of peri-operative
and quantitative measurement that uses the samemicro-infarction may differ from those of the acute
antibody pairs. Numerous studies in various groupscoronary syndromes, the potential for similar adverse
of cardiac patients attest to the value of cTnT inoutcome is worrying.
the early and accurate diagnosis of micro-infarction.There are now a number of therapies available that
However, there have been reports of cross reactivityhave been shown to reduce the mortality following
with skeletal muscle troponin T.27–30 This may havean acute coronary syndrome that include the use of
been due to a cross reactive antibody used with thebeta-blockers, low molecular weight heparins, the anti-
original assay kit (Enzymun Test System ES22, Boehr-platelet glycoprotein IIb/IIIa receptor antagonists and
inger Mannheim).31 The newer kit available utilisesearly coronary revascularisation.16–21 These therapies
two separate antibodies (ES300 CardiAC Troponin T,may have a similar important role in reducing the
Boehringer Mannheim) and these are reported to bemorbidity and mortality from peri-operative micro-
more reliable in their cardiac specificity.32 cTnT speci-infarction and the early accurate diagnosis of such
ficity may also be affected by the fact that it is expressedinjury is therefore critical. Cardiac troponin is one
in normal foetal and neonatal skeletal muscle.29 Al-such marker that is currently under investigation with
though its expression is normally suppressed in adultregard to its role in this diagnosis.
skeletal muscle it may also become elevated in disease
states such as polymyositis and dermatomyositis.33
Unexplained elevations of cTnT have also been ob-
served in patients with end stage renal failure under-
going renal replacement therapy.34,35 The possibility
exists in these patients that myocardial injury un-
Structural aspects of cardiac troponin detected by other means is occurring, although of note
in most of the patients studied cTnI was not elevated.28
The troponins are normal muscle proteins involved
in the calcium regulated, actin-myosin interactions.22
Three sub-types exist. Troponin T binds to tro-
pomyosin and attaches the troponin complex to the Clinical experience with cTnI
thin filament, troponin I binds to actin and inhibits
actin-myosin coupling and troponin C binds to calcium Numerous cTnI assay techniques are available (Table
2) that use differing antibodies pairs and differingand antagonises the effect of the troponin I.23 Most
troponin is tightly bound to this troponin complex but methods. There has been concern raised over the direct
comparison of the results obtained using these dif-about 6% of troponin T and 2–3% of troponin I is free
in the cytoplasm.24 fering assays.36 However, as cTnI is not expressed
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Table 1. Characteristics of Cardiac Troponin I and T.
Cardiac Earliest elevation following Peak level Time detectable Molecular mass
Troponin necrosis in circulation in circulation
cTnI 3–12 h 12 h 5–10 days 24 kD
cTnT 3–12 h 12–48 h 5–14 days 37 kD
Table 2. Cardiac Troponin I assays currently available, the lower detection limits determined for myocardial injury and studies that
have been conducted using the assays.
cTnI kit Manufacturer Assay type Lower limit of Studies using cTnI kit
detection of assay
cTnI antibody Wellcome Radioimmunoassay 10 ng/ml Cummins et al. (1987)42
Stratus Dade Immunofluorescence 1.5 ng/ml Adams et al. (1993),
Adams et al. (1994)8,23
93PTG127B Spectral Diagnostics Fluorogenic ELISA 0.2 ng/ml Bhayana et al. (1995)28
cTnI Baxter Diagnostics 2 step immunoassay 0.6 ng/ml Kollef et al. (1997),
Metzler et al. (1997)43,44
OPUS cTnI Dade Behring Fluorogenic ELISA 0.5 ng/ml Hegner et al. (1997)45
AxSYM Abbott Laboratories 2 step immunoassay 1 ng/ml Heeschen et al. (1999)46
Stratus II Baxter Dade Fluorometric 0.35 ng/ml Zaninotto et al. (1999),
Troponin I Khan et al. (1999)47,48
CTnI Beckman Access Paramagnetic 0.1 ng/ml Neill et al. (2000)41
chemiluminescence
immunoassay
Table 3. Peri-operative studies conducted using cardiac troponin as a marker for myocardial injury and its relation to cardiac events.
Study No. of Follow-up cTn cTn results Clinical cardiac events
patients period measured
+ve (%) −ve (%) Total no. cTn +ve (%) cTn −ve (%)
Adams et al. (1994)8 108 36 h I 9 (8.3) 99 (91.7) 8 8 (100) 0 (0)
Lee et al. (1996)39 1175 3 days T 199 (17) 976 (83) 31 23 (74) 8 (26)
Lopez et al. (1997)40 772 6 months T 92 (12) 580 (88) 19 8 (42) 11 (58)
Metzler et al. (1997)38 67 7 days T & I 13 (19.5) 54 (80.5) 13 8 (62) 5 (38)
Neill et al. (2000)41 80 3 months T & I T-4 (5) T-76 (95) 21 T-4 (19) T-17 (81)
I-6 (7.5) I-74 (92.5) I-6 (29) I-15 (71)
during development and there have been no reports to A further 19 patients had a CK-MB rise with no
echocardiographic changes, only one of whom had adate of cross reactivity with skeletal muscle troponins it
cTnI rise. They concluded that cTnI is of most benefitoffers theoretical advantages over cTnT in terms of
in avoiding the false negative diagnosis of cardiaccardiac specificity.27 In addition it follows a similar
injury with a raised CK-MB, but with no echo-time course with injury for release as cTnT and remains
cardiographic evidence of wall damage.elevated in the circulation for a similar time period.37
Metzler studied 67 patients undergoing a variety of
major abdominal, vascular and orthopaedic op-
erations.38 With serial measurement over a 7 day
Cardiac troponin in the peri-operative patient period, 13 patients (19.5%) had an increase in both
cTnT and cTnI. Eight patients had significant cardiac
Few published studies have examined the use of tro- events and relatively higher (>0.2 g l−1) cTnT levels.
ponin in the diagnosis of peri-operative MI in non- They concluded that the degree of cTn elevation re-
cardiac surgical patients (Table 3). Adams et al. re- flects the severity of injury and also suggested that
ported on 108 patients of whom 96 had undergone elevations of both cTnT and cTnI are necessary for
major vascular surgery.8 Eight patients suffered a peri- diagnosis.
operative MI as defined by echocardiographic de- Lee et al. studied cTnT in 1175 patients undergoing
tection of segmental wall defects. Of these, all had an major non-cardiac vascular surgery.39 cTnT was el-
evated in 87% of patients with a CK/CK-MB rise andassociated cTnI rise, but only 6 had a CK-MB rise.
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ECG changes diagnostic of peri-operative MI. This following surgery will have the same prognostic value
as in an acute coronary syndrome, there is somecompares with 16% of patients who had no evidence
of peri-operative MI. In those patients who had other evidence so far to support its use as a marker for
adverse outcome. Using troponin measurement tocardiac complications, cTnT was elevated in 62%, com-
pared with 15% of those with no complications. These diagnose peri-operative MI may allow for the early
risk stratification and appropriate treatment of patientsdata indicate that cTnT had a similar performance for
the diagnosis of definite MI as CK/CK-MB but a better who may be at a higher risk of peri-and post operative
cardiac events. The main limitation to its clinical usecorrelation with major cardiac complications where
no definite infarction could be identified. to date has been its lack of general availability, the
differing antibodies available and the lack of directThey concede however that asymptomatic cTnT rise
was common and that some 90% of patients with a comparison between these. Troponin assays are also
more expensive compared with other markers cur-rise suffered no apparent major cardiac complications.
This suggests the following possibilities: a lack of rently in routine clinical use. This increased cost must
obviously be balanced against the potential reductionspecificity of cTnT for cardiac injury; a lack of speci-
ficity for the antibodies against cTnT used in their in morbidity, mortality and a reduced in-patient hos-
pital stay that may result from earlier and more ap-assay or sub-clinical myocardial micro-infarction that
could not be detected other means. This question of propriate cardiac intervention.
the significance of an asymptomatic rise in troponin
is addressed by a later study from the same group.40
In this study, they examined an asymptomatic group
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